PHAXIAM Therapeutics (Euronext: PHXM), a biopharmaceutical company specializing in innovative treatments for severe and resistant bacterial infections, has recently announced updated real-life clinical data from patients treated under the compassionate status in Europe. The company's phage therapy has shown promising results, with an infection control rate of 79% at 3 months for patients with prosthetic joint infections (PJI), either due to Staphylococcus aureus or Pseudomonas aeruginosa. This high rate is a significant improvement over the standard of care (SoC) and demonstrates the potential of PHAXIAM's therapy in treating resistant infections.



PHAXIAM's compassionate use data, which includes more than 120 patients treated since 2017, shows an overall infection control rate of 75% at 3 months. The company's phage therapy has been well-tolerated, with no signs of local or systemic toxicity observed in clinical case series. The therapy has been administered through various routes, including local, intravenous, and nebulization, and has been used in combination with standard treatment, such as debridement, antibiotic therapy, and prosthesis maintenance (DAIR).

PHAXIAM's phage therapy has shown consistent results in both compassionate use cases and clinical trials. The PhagoDAIR pilot study, which recruited 29 patients with PJI, demonstrated an infection control rate of 74% in the "Phages" experimental arm, with 14 out of 19 patients achieving infection control after a single intra-articular injection. The consolidated infection control rate, including patients who received rescue medication after relapse, was 80% (16/20). These encouraging results validate the decision to launch the GLORIA Phase II POC trial, which will enroll 100 patients in Europe and the United States from Q1 2025 onwards.

PHAXIAM's phage therapy has the potential to adapt to different patient needs and market demands, as it has shown promise in treating various indications, including osteomyelitis, vascular infections, and lung infections. The therapy's versatility allows it to be administered through different routes, making it a valuable tool in the fight against resistant infections. PHAXIAM is planning to file for another AAC to treat patients with resistant P. aeruginosa infections, further expanding the eligible population to its phages under a compassionate status.

In conclusion, PHAXIAM Therapeutics' phage therapy has shown promising results in treating resistant bacterial infections, with a high infection control rate and excellent safety profile. The company's compassionate use data and clinical trial results demonstrate the potential of its therapy in treating severe and resistant infections, positioning it as a promising player in the market. As PHAXIAM continues to develop and expand its phage therapy, it has the potential to make a significant impact on patient outcomes and improve the lives of those affected by resistant infections.